Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
39.75
-0.16 (-0.40%)
Dec 20, 2024, 4:00 PM EST - Market closed
Surmodics Revenue
In the fiscal year ending September 30, 2024, Surmodics had annual revenue of $126.08M, down -4.91%. Surmodics had revenue of $33.23M in the quarter ending September 30, 2024, with 18.80% growth.
Revenue (ttm)
$126.08M
Revenue Growth
-4.91%
P/S Ratio
4.46
Revenue / Employee
$324,108
Employees
389
Market Cap
569.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 126.08M | -6.51M | -4.91% |
| Sep 30, 2023 | 132.58M | 32.63M | 32.65% |
| Sep 30, 2022 | 99.95M | -5.19M | -4.93% |
| Sep 30, 2021 | 105.14M | 10.27M | 10.83% |
| Sep 30, 2020 | 94.86M | -5.21M | -5.21% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fulgent Genetics | 277.76M |
| OrthoPediatrics | 189.67M |
| SI-BONE | 157.04M |
| GRAIL | 117.67M |
| Simulations Plus | 70.01M |
| Capricor Therapeutics | 23.23M |
| CorMedix | 12.26M |
| Altimmune | 52.00K |
SRDX News
- 6 weeks ago - Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Business Wire
- 7 weeks ago - Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System - Business Wire
- 2 months ago - Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter - Business Wire
- 5 months ago - Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results - Business Wire
- 5 months ago - SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX - Business Wire
- 6 months ago - Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. - Business Wire
- 7 months ago - SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX - Accesswire
- 7 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc. - PRNewsWire